drugset / Trial / NCT05940428
A Study of ASKG712 in Patients With Diabetic Macular Edema
Phase 1
Completed
10 enrolled
Visara, Inc.
AskGene Pharma, Inc. · collabSuzhou Aosaikang Biopharmaceutical Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema (DME).
Timeline
- Start
- 2023-10-23
- Primary completion
- 2024-10-21
- Completion
- 2024-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKG712 | Monoclonal antibody | — | Intravitreal |